Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2128-2135

  Yardley, Denise A ^a   Ismail Khan, Roohi R ^b   Melichar, Bohuslav ^c   Lichinitser, Mikhail ^d   Munster, Pamela N ^e   Klein, Pamela M ^f,g   Cruickshank, Scott ^g   Miller, Kathy D ^h   Lee, Min J ⁱ   Trepel, Jane B ⁱ  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PMK Consulting   (United States)

^g Syndax Pharmaceuticals   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENTINOSTAT; EXEMESTANE; LYSINE; PLACEBO; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BENZAMIDE DERIVATIVE; ESTROGEN RECEPTOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD ANALYSIS; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; HYPOXIA; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ACETYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BENZAMIDES; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PYRIDINES; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84879834815     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.7251     Document Type: Article

References (27)

1. Chia S, Gradishar W, Mauriac L, et al: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26:1664-1670, 2008
2. Sabnis GJ, Goloubeva O, Chumsri S, et al: Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 71:1893-1903, 2011
3. Sabnis GJ, Kazi A, Goloubeva O, et al: HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr PD05-03)
4. Chung EJ, Lee S, Sausville EA, et al: Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci 35:397-406, 2005
5. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
6. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assn 53:457-481, 1958
8. Knipstein J, Gore L: Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs 20:1455-1467, 2011
9. Wardley A, Stein R, McCaffrey J, et al: Results of a phase 2 study of entinostat, an oral, class 1 selective histone deacetylase inhibitor, added to maintained aromatase inhibitor therapy in patients whose breast cancer is progressing on hormone therapy. J Clin Oncol 28:126s, 2010 (suppl; abstr 1052)
10. Hodges-Gallagher L, Valentine CD, Bader SE, et al: Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105: 297-309, 2007
11. Thomas S, Thurn KT, Biçaku E, et al: Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 130:437-447, 2011
12. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
13. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 366:520-529, 2012
14. Kummar S, Gutierrez M, Gardner ER, et al: Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 13: 5411-5417, 2007
15. Ryan QC, Headlee D, Acharya M, et al: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922, 2005
16. Zain J, O’Connor OA: Targeting histone deacetylases in the treatment of B- and T-cell malignancies. Invest New Drugs 28:S58-S78, 2010 (abstr S58)
17. Tan J, Cang S, Ma Y, et al: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3:5, 2010
18. Acharya MR, Sparreboom A, Venitz J, et al: Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 68:917-932, 2005
19. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007
20. Piekarz RL, Frye R, Prince HM, et al: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117:5827-5834, 2011
21. Whittaker SJ, Demierre MF, Kim EJ, et al: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485-4491, 2010
22. Piekarz RL, Frye AR, Wright JJ, et al: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12:3762-3773, 2006
23. Piekarz RL, Frye R, Turner M, et al: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417, 2009
24. Molife R, Fong P, Scurr M, et al: HDAC inhibitors and cardiac safety. Clin Cancer Res 13:1068, 2007
25. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728, 2002
26. Giles F, Fischer T, Cortes J, et al: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628-4635, 2006
27. Yardley DA, Ismail-Khan RR, Klein PM: Entinostat, a novel histone deacetylase inhibitor, added to exemestane improves PFS in advanced breast cancer in a randomized, phase II, double-blind study. Cancer Res 71:118s, 2011 (suppl; abstract PD01-04)